Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02532452 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Third Party Viral Specific T-cells (VSTs)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Dec 2026 → Dec 2028
See other at-risk trials from Children's Hospital Medical Center, Cincinnati

Record History

  1. Primary completion pushed from Dec 2026 to Dec 2028 Enrollment increased: 750 → 1000 participants · Completion pushed from Dec 2027 to Dec 2029v19 Show 2 more changesShow less
    • Enrollment increased: 750 → 1000 participants
    • Completion pushed from Dec 2027 to Dec 2029
  2. Site contacts updated at 1 of 4 sitesv18
  3. Re-verified, no change to tracked fieldsv17
  4. Site details revised at 1 of 4 sites Eligibility criteria expanded, about 4 wordsv16 Show 1 more changeShow less
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  5. Enrollment target: 450 to 750 Eligibility criteria expanded, about 27 wordsv15 Show 1 more changeShow less
    • Eligibility criteria expanded, about 27 words

    See this version in full on ClinicalTrials.gov ↗

Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 3 to 4v14
  2. Primary completion date: Mar 2023 to Dec 2026 Completion date: Mar 2024 to Dec 2027v13 Show 1 more changeShow less
    • Completion date: Mar 2024 to Dec 2027
  3. Study sites: 1 to 3v12
  4. Re-verified, no change to tracked fieldsv11
  5. Primary completion date: Aug 2021 to Mar 2023 Completion date: Aug 2022 to Mar 2024v10 Show 1 more changeShow less
    • Completion date: Aug 2022 to Mar 2024
  6. Enrollment target: 100 to 450 Primary endpoints: 1 to 3 · Interventions: Viral Specific CTL Infusion (Biological) to Viral Specific VST Infusion (Biological) · Secondary endpoints: 1 to 2 · 3 morev9 Show 6 more changesShow less
    • Primary endpoints: 1 to 3
    • Interventions: Viral Specific CTL Infusion (Biological) to Viral Specific VST Infusion (Biological)
    • Secondary endpoints: 1 to 2
    • Study description expanded, about 6 words
    • Eligibility criteria expanded, about 4 words
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  7. Site contact updatedv8
  8. Re-verified, no change to tracked fieldsv7
  9. Start date: Aug 2015 to Sep 2, 2015 Eligibility criteria revised · Study description expanded, about 3 wordsv6 Show 2 more changesShow less
    • Eligibility criteria revised
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  10. 3 versions Re-verified since Jul 6, 2016, no change to tracked fieldsv3-v5
  11. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
Trial Details
NCT Number NCT02532452
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Conditions Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov